From MedPage Today:
A genetically engineered clot-buster improved clinical outcomes compared with standard thrombolytic therapy in a selected population of people with ischemic strokes, researchers reported.
In an open-label phase IIb randomized trial, tenecteplase (TNKase) also did better than alteplase (Activase) in re-establishing blood flow to the affected brain regions, according to Mark Parsons, MD, of John Hunter Hospital in Newcastle, Australia, and colleagues.
Both drugs were equally safe, Parsons and colleagues reported in the March 22 issue of the New England Journal of Medicine.
Filed under: Uncategorized